Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine. 1987

M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman

We studied the influence of cimetidine on the gastroscopically visible effects of a single 1296-mg dose of aspirin. An initial dose-response study in 48 subjects showed that 200- and 400-mg doses of cimetidine conferred a sufficient reduction in gastric mucosal injury to warrant further study. A second study showed that coadministration of a single 200- or 400-mg cimetidine tablet with the aspirin conferred the same degree of injury reduction as when cimetidine was given before the aspirin. Reduction in mucosal injury by a 200-mg cimetidine tablet, coadministered with four aspirin tablets, was then compared to placebo in a double-blind trial. A reduction of mucosal injury was observed in 14 of 20 (70%) subjects receiving cimetidine and 0 of 10 subjects receiving placebo (P less than 0.001). Two hundred milligrams of cimetidine is therefore a rational dose for further studies of the reduction of chronic aspirin-induced gastric mucosal injury.

UI MeSH Term Description Entries
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D005773 Gastroscopy Endoscopic examination, therapy or surgery of the interior of the stomach. Gastroscopic Surgical Procedures,Surgical Procedures, Gastroscopic,Gastroscopic Surgery,Surgery, Gastroscopic,Gastroscopic Surgeries,Gastroscopic Surgical Procedure,Gastroscopies,Procedure, Gastroscopic Surgical,Procedures, Gastroscopic Surgical,Surgeries, Gastroscopic,Surgical Procedure, Gastroscopic
D006471 Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Hematochezia,Hemorrhage, Gastrointestinal,Gastrointestinal Hemorrhages,Hematochezias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
October 1987, Alimentary pharmacology & therapeutics,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
December 1977, Annals of internal medicine,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
November 2010, Nihon rinsho. Japanese journal of clinical medicine,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
January 1993, Journal of clinical gastroenterology,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
February 1978, Gastroenterology,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
September 1997, Pharmacology,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
May 1986, Gut,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
September 1966, Gastroenterology,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
October 1993, Alimentary pharmacology & therapeutics,
M B Kimmey, and F E Silverstein, and D R Saunders, and R C Chapman
December 1992, The American journal of physiology,
Copied contents to your clipboard!